While PET scans have been used to predict Hodgkin lymphoma outcomes, adding Adcetris to frontline therapy improved outcomes for patients, regardless of their results.
The incorporation of brentuximab vedotin (Adcetris) into the frontline treatment of patients with Hodgkin lymphoma correlates with superior efficacy, irrespective of PET2 results, suggesting loss of predictive value with the scan.